Delsona Therapeutics

Executive Summary

Delsona Therapeutics is a clinical-stage biotechnology company developing UltraNav, a novel focused ultrasound platform designed to transiently and locally open the blood-brain barrier (BBB) for non-invasive drug delivery to the central nervous system. Founded in 2021 and headquartered in Cambridge, MA, the company addresses major unmet needs in CNS diseases, including pediatric brain cancer and Alzheimer's disease. By enabling targeted delivery of therapeutics across the BBB, UltraNav has the potential to transform treatment paradigms for conditions that are historically difficult to treat due to the protective nature of the BBB. Delsona's approach offers advantages over traditional invasive methods, such as reduced systemic toxicity and improved patient outcomes. The company is currently advancing its lead programs through preclinical and early clinical development. Delsona's platform has demonstrated the ability to safely and repeatedly open the BBB in animal models, and initial human studies are underway to validate its clinical utility. The company is primarily focused on initiating Phase 1/2 trials for glioblastoma and pediatric brain tumors, while also preparing for Alzheimer's disease studies. With a strong intellectual property portfolio and strategic collaborations, Delsona is positioned to become a leader in CNS drug delivery. The success of ongoing trials and upcoming milestones will be critical for the company's near-term value creation and long-term growth.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 Interim Data for UltraNav in Pediatric Brain Cancer45% success
• Q2 2026FDA IND Clearance for Alzheimer's Disease Trial70% success
• TBDStrategic Partnership or Licensing Deal for UltraNav Platform35% success